Fredun Pharmaceuticals Limited Share Price

BSE: 539730

₹ 899.75

+₹3.45 (0.38%)

Last updated 24 Jul, 2026, 15:29 IST

Fredun Pharmaceuticals Limited Share Price Today

As of 25 Jul 2026, Fredun Pharmaceuticals Limited share price is ₹899.75. The stock opened at ₹895.00, compared to its previous close of ₹896.30. During today's trading session, Fredun Pharmaceuticals Limited share price moved in the range of ₹851.70 to ₹909.95, with an average price of ₹880.83 for the day. Looking at its last 52-week, the stock has touched a low of ₹300.03 and a high of ₹999.00.

₹851.70

0.38% up today

₹909.95

1D LOW

1D HIGH

Latest Earning

Op Profit TrendUp by 70.97% YoY

Latest Earning

Net Profit TrendUp by 2.86% QoQ

Latest Earning

Revenue TrendUp by 32.40% QoQ

Stock Performance

OutperformingBeat Nifty by 7.58 % in last 1 month

Shareholding Pattern

FIIFII increased stake by 0.56%

Fredun Pharmaceuticals Limited Returns Calculator

If you would've invested

₹

₹1,000₹1Cr

Historical Returns

1 Year

₹14,49,717+₹9,49,717 (+189.94%)

3 Year

₹11,51,975+₹6,51,975 (+130.40%)

5 Year

₹32,32,936+₹27,32,936 (+546.59%)

₹716.20₹1,074.20

Circuit Low

Circuit High

₹300.03₹999.00

52-Week Low

52-Week High

Circuit

₹716.20

₹1,074.20

52-week

₹300.03

₹999.00

Mkt Cap Cr

1,480.49

P/E

28.05

P/B

3.46

ROE

15.55%

D/E

0.92

ROCE

21.12%

Div. Yield

0.04%

EPS(TTM)

68.01

Turnover

1.83

EV/EBITDA

11.34

Net Margin

5.23%

Op. Margin

14.92%

ROA

6.46%

Quick Ratio

0.77

Curr. Ratio

1.45

Mkt Cap Cr

1,480.49

P/E

28.05

P/B

3.46

ROE

15.55%

D/E

0.92

ROCE

21.12%

Div. Yield

0.04%

EPS(TTM)

68.01

Turnover

1.83

EV/EBITDA

11.34

Net Margin

5.23%

Op. Margin

14.92%

ROA

6.46%

Quick Ratio

0.77

Curr. Ratio

1.45

Based on fundamentals, this stock's

Performance

Excellent

Fredun Pharma outperforming all market indices

Valuation

Overvalued

Fredun Pharma appears overvalued compared to its peers

Earnings

Excellent

Fredun Pharma revenue, operating profit and net profit are growing

Peer Comparison

Peer comparison — key ratios
Name	Mkt Cap Cr	P/E	P/B	ROE	D/E	ROCE	Book Value	Div. Yield	Turnover	EPS(TTM)
Sun Pharmaceutical Industries	4,65,711.00	36.73	5.05	14.85%	0.55	18.72%	18.85	0.91%	0.56	10.90
Divis Laboratories	1,93,860.00	61.36	9.40	16.19%	0.00	21.00%	9.43	0.50%	0.58	98.19
Torrent Pharmaceuticals	1,92,687.00	66.03	17.03	26.76%	1.05	18.30%	16.90	0.90%	0.49	64.75
Cipla	1,12,593.00	33.96	3.31	11.27%	0.00	14.95%	423.36	0.92%	0.45	43.52
Zydus Lifesciences	1,11,082.00	17.39	3.23	19.69%	0.35	20.30%	3.70	0.11%	0.39	35.38
Lupin	1,09,553.00	19.83	4.71	27.01%	0.03	27.44%	3.51	0.78%	0.61	129.18
Mankind Pharma	1,03,472.00	1.05	0.12	12.65%	0.42	12.97%	5.05	0.05%	0.54	49.37
Dr. Reddy's Laboratories	96,204.70	30.22	2.53	11.07%	0.18	12.54%	377.96	0.69%	0.41	38.68
Aurobindo Pharma	88,508.40	25.27	2.34	9.25%	0.19	11.76%	391.14	0.26%	0.48	41.58
Laurus Labs	84,727.30	79.36	16.33	16.77%	0.40	16.14%	97.21	0.12%	0.64	13.72

Fredun Pharmaceuticals Limited Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
Particulars	Mar 2026	Mar 2025
Revenue	₹635.47	₹453.82
Other Income	₹3.66	₹2.45
Total Revenue	₹639.12	₹456.27
Total Expenses	₹592.13	₹428.78
Profit Before Tax	₹47.00	₹27.49
Tax	₹14.38	₹7.75
Profit After Tax	₹32.62	₹19.74
EPS - Basic	₹66.81	₹41.78
EPS - Diluted	₹61.23	₹42.53

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
Particulars	Mar 2026	Mar 2025
Profit before tax	₹32.62	₹20.03
Income before WC changes	₹80.84	₹55.09
Change in Assets	-₹28.56	-₹169.59
Change in Liabilities	-₹39.37	₹97.91
Change in WC	-₹67.93	-₹71.68
Cash flow from Operations	₹11.90	-₹16.60
Cash flow from Investing	-₹73.59	-₹6.35
Cash flow from Financing	₹121.45	₹26.65
Total Cash Flow	₹59.76	₹3.70
Cash (Start of the year)	₹5.22	₹1.52
Cash (End of the year)	₹64.98	₹5.22

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
Particulars	Mar 2026	Mar 2025
Non-Current Assets	₹143.91	₹60.21
Current Assets	₹498.17	₹427.20
Total Assets	₹642.08	₹487.41
Current Liabilities	₹296.86	₹328.10
Net Current Asset	₹201.31	₹99.11
Non-Current Liabilities	₹67.11	₹17.93
Equity Capital	₹278.11	₹141.38
Total Equity & Liabilities	₹642.08	₹487.41

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Revenue	₹635.47	₹453.82	₹348.16	₹274.68
Other Income	₹3.66	₹2.45	₹0.92	₹1.82
Total Revenue	₹639.12	₹456.27	₹349.07	₹276.50
Total Expenses	₹591.54	₹428.00	₹327.62	₹258.99
Profit Before Tax	₹47.58	₹28.27	₹21.45	₹17.51
Tax	₹14.38	₹7.46	₹5.83	₹6.70
Profit After Tax	₹33.21	₹20.81	₹15.62	₹10.81
EPS - Basic	₹68.01	₹44.83	₹33.81	₹24.13
EPS - Diluted	₹62.33	₹44.37	₹33.47	₹22.93

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Profit before tax	₹33.21	₹20.81	₹15.62	₹10.76
Income before WC changes	₹81.10	₹55.27	₹38.22	₹29.16
Change in Assets	-₹25.15	-₹174.13	-₹54.39	-₹62.33
Change in Liabilities	-₹39.93	₹96.41	₹15.73	₹18.76
Change in WC	-₹65.08	-₹77.72	-₹38.66	-₹43.57
Cash flow from Operations	₹16.44	-₹20.98	-₹0.44	-₹14.41
Cash flow from Investing	-₹73.58	-₹5.99	-₹7.64	-₹9.40
Cash flow from Financing	₹121.82	₹25.90	₹5.99	₹25.18
Total Cash Flow	₹64.67	-₹1.07	-₹2.08	₹1.36
Cash (Start of the year)	₹0.28	₹1.35	₹3.44	₹2.07
Cash (End of the year)	₹64.95	₹0.28	₹1.35	₹3.44

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
Particulars	Mar 2026	Mar 2025	Mar 2024	Mar 2023
Non-Current Assets	₹143.89	₹64.40	₹50.46	₹41.07
Current Assets	₹498.24	₹422.25	₹257.14	₹216.21
Total Assets	₹642.14	₹486.65	₹307.60	₹257.28
Current Liabilities	₹296.31	₹327.32	₹166.83	₹139.66
Net Current Asset	₹201.93	₹94.93	₹90.31	₹76.55
Non-Current Liabilities	₹67.11	₹17.93	₹19.30	₹21.25
Equity Capital	₹278.71	₹141.40	₹121.47	₹96.38
Total Equity & Liabilities	₹642.14	₹486.65	₹307.60	₹257.28

* All values are in INR Crore

Qty

Bid

Ask

Qty

Bid Total: 0

Ask Total: 0

Buy orders: 0%

Sell orders: 0%

30 levels of bid & ask depth

Supply & Demand Zones

Bearish

Neutral

Bullish

Slightly Bullish

by SEBI experts available for this stock

Earn more using advisory

by SEBI experts

Expert Pick

EXPPICK

Stop-loss

Entry price

Target

Indicator

Value

Verdict

RSI (14)

51.27

Neutral

ATR (14)

50.98

Neutral

STOCH(9,6)

29.53

Neutral

STOCH RSI (14)

7.42

Bullish

ADX(9)

20.41

Bearish

UO(9)

56.63

Neutral

ROC(12)

4.16

Bullish

WillR(14)

-63.41

Neutral

Period

Simple value

Exponential vaue

904.1

905.14

10D

928.18

909.95

20D

907.82

899.31

50D

848.52

846.43

100D

736.7

772.21

About Fredun Pharmaceuticals Limited

ISIN

INE194R01017

Sector Market Cap

₹ 1,480.49 Cr

Fredun Pharmaceuticals Ltd. is an India-based pharmaceuticals formulation manufacturing company. The Company is engaged in manufacturing dietary/herbal supplements, nutraceuticals, and other healthcare products, along with animal healthcare products. Its segment includes Fredun Generics, Pet Care, Nutraceuticals, Cosmeceuticals and Mobility. Its Generics Division, marketed under the Fredun Gx brand. The Pet Healthcare segment operates under the Freossi brand. The Nutraceutical Division under Fredun Nutrition brand. Its Cosmeceuticals Division, operating under the Bird N Beauty (BNB) and Beautyfred brands, is focused on skincare and personal care products. Its Mobility Division, operating under Chuu Balm, BraceOn, NebOn, and DigiOn, caters to the ortho rehabilitation aids and pain management market. It offers a range of products, including antihypertensive, antidiabetic, antiretroviral drugs (ARVs) and narcotics. It also provides comprehensive pet care technology platforms.

Fredun Pharmaceuticals Limited Financial Highlights

Revenue: Fredun Pharmaceuticals Limited reported revenue of ₹639.12 crore in FY26 vs ₹456.27 crore in FY25. It showed an increase of 40.07% on a yearly basis.
Operating Profit: Fredun Pharmaceuticals Limited reported an operating profit of ₹47.00 crore in FY26 vs ₹27.49 crore in FY25. It showed an increase of 70.97% on a year-on-year basis.
Net Profit: Fredun Pharmaceuticals Limited reported a net profit of ₹32.62 crore in FY26 vs ₹19.74 crore in FY25. It showed an increase of 65.25% on a yearly basis.

Fredun Pharmaceuticals Limited Quarterly Result Highlights

Fredun Pharmaceuticals Limited reported revenue of ₹213.06 crore in Mar 2026, compared with ₹160.92 crore in Dec 2025, representing an increase of 32.40% on a quarter-on-quarter (QoQ) basis.
Fredun Pharmaceuticals Limited reported an operating profit of ₹11.25 crore in Mar 2026, compared with ₹14.00 crore in Dec 2025, representing a decrease of 19.64% on a quarter-on-quarter (QoQ) basis.
Fredun Pharmaceuticals Limited reported a profit of ₹10.78 crore in Mar 2026, compared with ₹10.48 crore in Dec 2025, reflecting an increase of 2.86% on a QoQ basis.
The earnings per share (EPS) of Fredun Pharmaceuticals Limited stood at ₹66.81 during Mar 2026.